Table 1.
Patient demographic, disease measures, csDMARD use and orthopaedic surgery by DAS28 category
| DAS28 categories | |||||
|---|---|---|---|---|---|
| Remission | Low | Low-moderate | High-moderate | High | |
| Total n (%) | 425 (21) | 301 (15) | 524 (26) | 426 (21) | 369 (18) |
| Females (%) | 52 | 57 | 69 | 77 | 82 |
| Age RA onset (mean, SD) |
53.4, 14.0 | 55.5, 13.9 | 55.8, 13.6 | 55.7, 14.5 | 56.5, 13.6 |
| Baseline ESR mm/h (median, IQR) |
20, 32 | 28, 34 | 33, 43 | 37, 42 | 42, 40 |
| Baseline Hb (mean, SD) |
13.1, 1.45 | 13.1, 1.51 | 12.9, 1.50 | 12.6, 1.60 | 12.4, 1.54 |
| Baseline DAS28 (mean, SD) |
4.00, 1.42 | 4.47, 1.27 | 4.76, 1.21 | 5.32, 1.16 | 5.82, 1.05 |
| Baseline HAQ (mean, SD) |
0.81, 0.70 | 0.91, 0.70 | 1.07, 0.71 | 1.29, 0.71 | 1.59, 0.73 |
| Baseline BMI (median, IQR) |
25, 5.28 | 25, 4.87 | 26, 6.24 | 26, 6.58 | 26, 6.20 |
| csDMARDs by 1 year (n, %) |
369, 86.8 | 251, 83.4 | 471, 89.9 | 396, 93.0 | 356, 96.5 |
| csDMARDs weeks to start (median, IQR) |
2, 0–6 | 2, 0–13 | 2, 0–9 | 2, 0–6 | 2, 0–6 |
| bDMARDs by 1 year (n, %) |
6, 1.4 | 1, 0.3 | 3, 0.6 | 1, 0.2 | 4, 1.1 |
BMI, body mass index; DAS, disease activity score; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; csDMARDs, conventional synthetic disease modifying antirheumatic drugs; Hb, haemoglobin; RA, rheumatoid arthritis; bDMARDs, biologics DMARD.